July 2019 Br J Cardiol 2019;26(suppl 2):S10–S14 doi:10.5837/bjc.2019.s09
Paul Guyler
Introduction Atrial fibrillation (AF) more than doubles the five-year risk of stroke in middle-aged men and women.1 Prior cerebrovascular disease markedly amplifies the risk of recurrent stroke in patients with or without AF.1,2 Figure 1 shows the influence of AF and prior cerebrovascular disease (stroke or transient ischaemic attack [TIA]) on the estimated five-year risk of a composite of stroke, systemic thromboembolism, or TIA (most events were ischaemic strokes) for a 60-year-old individual, from a large cohort study conducted in the UK.1 These observations demonstrate the need for long-term treatment to reduce the risk of stroke in thes
May 2019 Br J Cardiol 2019;26:52
BJC Staff
Stat tests loaded into the VITROS XT 7600 Moderate alcohol consumption does not protect against stroke Blood pressure and stroke risk increase steadily with increasing alcohol intake, and previous claims that one to two alcoholic drinks a day might protect against stroke are not borne out by new evidence from a genetic study involving 160,000 adults. Studies of East Asian genes, where two common genetic variants strongly affect what people choose to drink, show that alcohol itself directly increases blood pressure and the chances of having a stroke, according to a new study published in The Lancet (doi: 10.1016/S0140-6736(18)31772-0). Researc
July 2014 Br J Cardiol 2014;21:102
Paul Guyler
GTN in acute stroke Dr Paul Guyler (Southend University Hospital NHS Trust) A number of major randomised controlled trials reported final results at the meeting, including the ENOS (Efficacy Of Nitric Oxide In Stroke) trial. Nitric oxide (NO) has multiple actions and is a potential candidate for the treatment of acute stroke. Among the properties which may be beneficial are lowering blood pressure, cerebral vasodilation, and improvements in central and systemic haemodynamics. NO donors are effective in experimental stroke, and pilot studies in patients suggest that one, glyceryl trinitrate (GTN), can be delivered easily as a transdermal prepa
May 2004 Br J Cardiol 2004;11:235-8
Joseph de Bono, Lucy Hudsmith, Grant Heatlie
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits